Let’s start up with the current stock price of ADMA Biologics Inc. (ADMA), which is $1.35 to be very precise. The Stock rose vividly during the last session to $1.32 after opening rate of $1.26 while the lowest price it went was recorded $1.26 before closing at $1.30.Recently in News on December 21, 2021, ADMA Biologics Adopts Limited Duration Stockholder Rights Plan. ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a 6-month term stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one right (the “Right”) for each outstanding share of common stock. The record date for the dividend distribution is December 30, 2021. The Rights Plan will expire, without any further action required to be taken by ADMA’s Board of Directors, on June 15, 2022. You can read further details here
ADMA Biologics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.4900 on 01/04/22, with the lowest value was $1.2600 for the same time period, recorded on 01/13/22.
ADMA Biologics Inc. (ADMA) full year performance was -38.39%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ADMA Biologics Inc. shares are logging -56.60% during the 52-week period from high price, and 33.66% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.01 and $3.11.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 906983 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the ADMA Biologics Inc. (ADMA) recorded performance in the market was -7.80%, having the revenues showcasing 17.12% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 250.72M, as it employees total of 406 workers.
Market experts do have their say about ADMA Biologics Inc. (ADMA)
During the last month, 3 analysts gave the ADMA Biologics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.3029, with a change in the price was noted -0.01. In a similar fashion, ADMA Biologics Inc. posted a movement of -0.74% for the period of last 100 days, recording 2,703,241 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ADMA is recording 0.92 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.92.
Technical breakdown of ADMA Biologics Inc. (ADMA)
Raw Stochastic average of ADMA Biologics Inc. in the period of last 50 days is set at 35.29%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 56.25%. In the last 20 days, the company’s Stochastic %K was 43.75% and its Stochastic %D was recorded 45.14%.
Bearing in mind the latest performance of ADMA Biologics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -7.80%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -15.03%, alongside a downfall of -38.39% for the period of the last 12 months. The shares increased approximately by -0.76% in the 7-day charts and went down by 2.36% in the period of the last 30 days. Common stock shares were driven by 17.12% during last recorded quarter.